Trial Outcomes & Findings for A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (NCT NCT06267001)

Last Updated: 2026-06-10

Results Overview

An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention.

Recruitment status

TERMINATED

Study phase

PHASE3

Target enrollment

56 participants

Primary outcome timeframe

Up to 16.4 months

Results posted on

2026-06-10

Participant Flow

A total of 56 participants with programmed death-ligand 1 (PD-L1)-positive Stage IIB, IIIA, or select IIIB (T3N2 only) non-small cell lung cancer (NSCLC) following resection and adjuvant platinum-based chemotherapy took part in the study at 35 investigative sites in 10 countries from 21 March 2024 to 16 December 2025.

Participants were randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.

Participant milestones

Participant milestones
Measure	Atezolizumab + Placebo Participants received atezolizumab, 1680 milligrams (mg), in combination with or without placebo as intravenous (IV) co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.	Tiragolumab + Atezolizumab Participants received a fixed dose of tiragolumab, 840 mg, in combination with atezolizumab, 1680 mg as IV co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.
Overall Study STARTED	27	29
Overall Study Safety Analysis Set (SAS)	28	24
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	27	29

Reasons for withdrawal

Reasons for withdrawal
Measure	Atezolizumab + Placebo Participants received atezolizumab, 1680 milligrams (mg), in combination with or without placebo as intravenous (IV) co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.	Tiragolumab + Atezolizumab Participants received a fixed dose of tiragolumab, 840 mg, in combination with atezolizumab, 1680 mg as IV co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.
Overall Study Death	2	0
Overall Study Disease Recurrence	0	1
Overall Study Study Terminated by Sponsor	22	23
Overall Study Withdrawal by Subject	3	5

Baseline Characteristics

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Atezolizumab + Placebo n=27 Participants Participants received atezolizumab, 1680 mg, in combination with or without placebo as IV co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.	Tiragolumab + Atezolizumab n=29 Participants Participants received a fixed dose of tiragolumab, 840 mg, in combination with atezolizumab, 1680 mg as IV co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.	Total n=56 Participants Total of all reporting groups
Age, Continuous	65.3 years STANDARD_DEVIATION 9.3 • n=9 Participants	66.4 years STANDARD_DEVIATION 6.8 • n=27 Participants	65.9 years STANDARD_DEVIATION 8.1 • n=267 Participants
Sex: Female, Male Female	6 Participants n=9 Participants	8 Participants n=27 Participants	14 Participants n=267 Participants
Sex: Female, Male Male	21 Participants n=9 Participants	21 Participants n=27 Participants	42 Participants n=267 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	2 Participants n=9 Participants	3 Participants n=27 Participants	5 Participants n=267 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	25 Participants n=9 Participants	26 Participants n=27 Participants	51 Participants n=267 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=9 Participants	0 Participants n=27 Participants	0 Participants n=267 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=9 Participants	0 Participants n=27 Participants	0 Participants n=267 Participants
Race (NIH/OMB) Asian	22 Participants n=9 Participants	20 Participants n=27 Participants	42 Participants n=267 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=9 Participants	0 Participants n=27 Participants	0 Participants n=267 Participants
Race (NIH/OMB) Black or African American	0 Participants n=9 Participants	0 Participants n=27 Participants	0 Participants n=267 Participants
Race (NIH/OMB) White	4 Participants n=9 Participants	9 Participants n=27 Participants	13 Participants n=267 Participants
Race (NIH/OMB) More than one race	1 Participants n=9 Participants	0 Participants n=27 Participants	1 Participants n=267 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=9 Participants	0 Participants n=27 Participants	0 Participants n=267 Participants

PRIMARY outcome

Timeframe: Up to 16.4 months

Population: SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.

Outcome measures

Outcome measures
Measure	Atezolizumab ± Placebo n=28 Participants Participants received atezolizumab, 1680 mg, in combination with or without placebo as IV co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.	Tiragolumab + Atezolizumab n=24 Participants Participants received a fixed dose of tiragolumab, 840 mg, in combination with atezolizumab, 1680 mg as IV co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.
Number of Participants With Adverse Events (AEs)	26 Participants	21 Participants

Adverse Events

Atezolizumab ± Placebo

Serious events: 5 serious events

Other events: 23 other events

Deaths: 2 deaths

Tiragolumab + Atezolizumab

Serious events: 9 serious events

Other events: 21 other events

Deaths: 0 deaths

Serious adverse events

Other adverse events

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: Hoffmann-La Roche

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER

Measure	Atezolizumab ± Placebo n=28 participants at risk Participants received atezolizumab, 1680 mg, in combination with or without placebo as IV co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.	Tiragolumab + Atezolizumab n=24 participants at risk Participants received a fixed dose of tiragolumab, 840 mg, in combination with atezolizumab, 1680 mg as IV co-infusion on Day 1 of each 28-day cycle for up to 13 cycles in the absence of disease recurrence, or unacceptable toxicity.
Cardiac disorders Sinus node dysfunction	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Gastrointestinal disorders Gastrointestinal haemorrhage	3.6% 1/28 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	0.00% 0/24 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Infections and infestations COVID-19	3.6% 1/28 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	0.00% 0/24 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Infections and infestations Febrile infection	3.6% 1/28 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	0.00% 0/24 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Infections and infestations Pharyngitis	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Infections and infestations Pneumonia	3.6% 1/28 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	0.00% 0/24 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Infections and infestations Pulmonary tuberculosis	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Injury, poisoning and procedural complications Post procedural inflammation	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Musculoskeletal and connective tissue disorders Pathological fracture	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Musculoskeletal and connective tissue disorders Spinal stenosis	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Nervous system disorders Encephalitis autoimmune	3.6% 1/28 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	0.00% 0/24 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Renal and urinary disorders Nephritis	0.00% 0/28 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	4.2% 1/24 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Respiratory, thoracic and mediastinal disorders Lung consolidation	3.6% 1/28 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	0.00% 0/24 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.
Respiratory, thoracic and mediastinal disorders Pneumonitis	3.6% 1/28 • Number of events 1 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.	0.00% 0/24 • Up to 16.4 months SAS included all participants exposed to the study treatment, with participants analyzed according to the treatment actually received. Two participants randomized to the Tiragolumab + Atezolizumab arm did not receive tiragolumab and were treated with atezolizumab only, therefore, they were included in the Atezolizumab ± Placebo arm for safety analysis.